NASDAQ:MNPR - Monopar Therapeutics Stock Price, Forecast & News

Monopar Therapeutics trades on the NASDAQ under the ticker symbol "MNPR."

News headlines about MNPR stock have been trending very positive on Friday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Monopar Therapeutics earned a daily sentiment score of 3.9 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Monopar Therapeutics.

Some companies that are related to Monopar Therapeutics include Cytokinetics (CYTK), Collegium Pharmaceutical (COLL), Basilea Pharmaceutica (BPMUF), Homology Medicines (FIXX), Flexion Therapeutics (FLXN), Emisphere Technologies (EMIS), ImmunoGen (IMGN), TherapeuticsMD (TXMD), Retrophin (RTRX), DiaMedica Therapeutics (DMCAF), Omeros (OMER), Akero Therapeutics (AKRO), Cara Therapeutics (CARA), AC Immune (ACIU) and Axovant Sciences (AXON).

Based on aggregate information from My MarketBeat watchlists, some companies that other Monopar Therapeutics investors own include Applied Materials (AMAT), Splunk (SPLK), Coupa Software (COUP), Costco Wholesale (COST), Cara Therapeutics (CARA), Broadcom (AVGO), Arena Pharmaceuticals (ARNA), Anika Therapeutics (ANIK), Advanced Micro Devices (AMD) and Analog Devices (ADI).

(MNPR) raised $9 million in an initial public offering on Thursday, December 19th 2019. The company issued 1,100,000 shares at a price of $8.00 per share. JonesTrading acted as the underwriter for the IPO and Arcadia Securities was co-manager.

Monopar Therapeutics' quiet period expires on Tuesday, January 28th. Monopar Therapeutics had issued 1,111,112 shares in its public offering on December 19th. The total size of the offering was $8,888,896 based on an initial share price of $8.00. During the company's quiet period, underwriters and any insiders involved in the IPO are restricted from issuing any research reports for the company because of SEC regulations. Following the end of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Shares of MNPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MNPR stock can currently be purchased for approximately $16.62.

Monopar Therapeutics has a market capitalization of $176.01 million. Monopar Therapeutics employs 4 workers across the globe.View Additional Information About Monopar Therapeutics.

The official website for Monopar Therapeutics is http://www.monopartx.com/.

Monopar Therapeutics' mailing address is 5 REVERE DRIVE SUITE 200, NORTHBROOK IL, 60062. The company can be reached via phone at 614-395-8936 or via email at [email protected]